<DOC>
	<DOC>NCT01626872</DOC>
	<brief_summary>The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.</brief_summary>
	<brief_title>Long-Term Study of MP-214 in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Written informed consent obtained from the patient before the completion of Study A002A4 Patients who have completed the A002A4 study Patients who are experiencing ongoing, uncontrolled, clinically significant adverse events (AEs), as judged by the investigator (or subinvestigator)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Mental Disorder</keyword>
	<keyword>Psychotropic Drugs</keyword>
	<keyword>Dopamine Agents</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>